The authors evaluated the outcome and potential prognostic factors of 60 patients with surgically resected periampullary tumors.
Periampullary adenocarcinoma may arise from the mucosa ofthe ampulla of Vater, the pancreatic duct, the distal common bile duct, or the duodenum. Carcinomas originating from each of these sites exhibit different clinical behaviors. [1] [2] [3] [4] Despite radical surgical resection, the prognosis for most patients with periampullary carcinomas, particularly pancreatic ductal adenocarcinoma, is frustrating,5'6 however, a few long-term survivors have been identified. As with most malignant diseases, it is important to identify those patients who might survive for only a few months after pancreatectomy versus those for whom surgical resection would lead to long-term survival or cure.
If reliable prognostic factors can be identified before surgery, then the choice of surgery-pancreatectomy or a palliative procedure-would be made easier, and such identification and may even be valuable in choosing patients with tumors with poor prognosis for adjuvant treatment.
Our aim in the current study was to explore differences in the clinical evolution ofpancreatic and periampullary carcinomas and to evaluate potential prognostic factors.
METHODS
Of 417 patients with pancreatic and periampullary carcinoma who underwent surgery for palliation or resection at the Instituto Nacional de la Nutricion between 1960 and 1991, 60 patients were selected for analysis. This group represents all survivors of a potentially curative procedure (pancreatoduodenectomy or total pancreatectomy) during the study period.
A retrospective review of clinical histories and pathologic specimens of these patients was performed, and 15 different variables were analyzed. Resected specimens were re-examined by one of us (L.Q.) and tumors were divided into four groups according to the site of origin. In the group of patients with ampullary carcinoma, eight tumors were diploid and nine tetraploid, whereas most pancreatic tumors were diploid. The comparative ploidy distribution is shown in Figure 1 .
Median survival for patients with pancreatic, ampullary, and bile duct carcinoma was 18, 9, and 24 months, respectively. As for duodenal carcinoma, The last followup of patients with duodenal carcinoma was at 360 months, at which time a 75% survival rate was determined. Survival of patients according to type of carci- noma is summarized in Figure 2 . Differences among 5-year survival rates were marginally significant according to the log-rank test (p = 0.05).
Because only a small number of patients had tumors of the distal common bile duct and duodenum, only the group of patients with pancreatic and ampullary carcinomas were considered for the risk-factor analysis. The separate associations between several clinical, surgical, and pathologic characteristics with the time to recurrence of patients with pancreatic and ampullary tumors is presented in Table 3 .
In the group of patients with pancreatic carcinoma, disease-free survival was related to lymph node metastases, which were observed in 10 of the 20 patients. A statistically significantly improved survival rate was observed in patients with negative lymph nodes compared with patients with positive lymph nodes (Fig. 3) . In the group of patients with ampullary carcinoma, shorter survival was significantly associated with neural invasion and use of adjuvant chemotherapy. Figure 4 shows survival curves for the groups ofpatients in whom none, one, or both of these factors were present. Differences among these curves reached statistical significance (p = 0.007).
DISCUSSION Pancreatic Ductal Adenocarcinoma
Prognosis of patients with ductal adenocarcinoma of the pancreas is generally poor. Worldwide, the resectabil- ity rate for ductal adenocarcinoma of the pancreas ranges between 5% and 15%, morbidity and mortality rates are relatively high, and the 5-year survival rate is 4% to 7%.*2 During the 1960s and 1970s, the hospital mortality rate associated with pancreaticoduodenectomy was approximately 25%.'3 This rate changed dramatically during the 1 980s, and many centers now report hospital mortality rates ofless than 5%.14,15 However, despite improvements in surgical morbidity and mortality rates, even when the tumor can be resected and there is no evidence of regional or distant metastases, only a few patients survive 3 years or more after resection.5 6 Several researchers have sought to identify the determinants of long-term survival among patients with resectable adenocarcinoma of the pancreas. Factors associated with poor survival after resection have included perioperative blood transfusions, lymph node metastases, aneuploid DNA content, and increased tumor size. [16] [17] [18] Geer and Brennan, using both multivariate and univariate analysis in a study of 146 patients whose condition was cured by resection, found that tumors with poor histologic differentiation, tumors larger than 2.5 cm, and lymph node involvement were predictors ofsignificantly worse survival. '9 In contrast, in 1986 authors from the Mayo Clinic and survival.2' They found no difference in the DNA content analysis of patients with pancreatic ductal adenocarcinoma when comparing long-term and short-term survival after resection.
In the current study, using both separate and combined analysis, we found lymph node invasion to be the only independent factor for prognosis. This observation is in accordance with the results found by Geer and Brennan in their study at Memorial Sloan-Kettering Cancer Center (New York, New York). '9 Ampullary Carcinoma round-cell infiltrate at the tumor margin, and Carcinoma of the ampulla of Vater represents 4% to ial atypia in the uninvolved pancreatic duct, were 10% ofpatients with peripancreatic carcinoma and 0.2% antly associated with a poor prognosis. We be-of patients with malignant tumors ofthe gastrointestinal iese variables to be relatively unimportant because tract found at autopsy. tastases, margins, size, and resectability. Of these, resectability was found to be the only influencing factor.25 The median survival time for patients who underwent resection (51 months) was more than twice that of patients who did not undergo resection (8 months) . Recently, investigators at the Massachusetts General Hospital24 (Boston) conducted a study of 41 patients with ampullary carcinoma. Twelve patients with well-or moderately differentiated tumors limited to the ampulla or duodenum and with uninvolved lymph nodes and resection margins had 5-year local control and survival rates of 100% and 80%, respectively. In contrast, 17 patients with poorly differentiated tumors that had invaded the pancreas and with involved lymph nodes or positive resection margins had local control and survival rates of 50% and 38%, respectively. For 12 patients within this "high-risk" group (i.e., the group of 17 patients with poorly differentiated tumors) who also received postoperative radiation therapy after pancreatectomy, better local control usually resulted (83%), although survival did not improve.
To minimize the development of local recurrence, physicians have used adjuvant therapy for patients with ampullary carcinoma. Barton postoperative chemotherapy, in which 5-fluorouracil was the most common agent used in combination with doxorubicin, carmustine, vincristine, methyl-lomustine, or mitomycin. Sixteen patients (94%) had previously undergone a pancreaticoduodenectomy. Although no analysis was presented, the authors stated that "no combination of drugs appeared to prolong life when used in either the adjuvant or therapeutic setting." In contrast, Yeung and colleagues found no residual tumor in specimens of pancreatoduodenectomy performed for four patients with duodenal/ampullary carcinomas who had received neoadjuvant chemoradiation therapy.27
Our study showed better prognosis ofampullary carcinomas compared with pancreatic tumors and suggests that certain variables, such as the presence of neural invasion and the use of chemotherapy, influence prognosis. We agree that adjuvant and neoadjuvant therapies should be tested in controlled studies for this particular type of tumors.
Lower-Third Biliary Carcinoma
The location of the lesion appears to be the most important prognostic factor. Lesions in the lower third of Ann. Surg. * Novenber 1995 the biliary tract are the most resectable and are therefore associated with better results. The 5-year survival rate of patients in a study conducted by Tompkins et al. at the University of California at Los Angeles was 28%.28 Resectability in a study of distal-third biliary tumors at the Lahey Clinic (Boston, MA) resulted in 100% resectability. The median survival time was 16 months, and the 5-year survival rate was 20%. 3 In a recent study from Japan, the researchers analyzed the influence of various clinicopathologic factors on survival for 70 patients who underwent resection for bile duct carcinoma Japan.29 A univariate analysis revealed 10 factors associated with a significant outcome. However, when the interactive effects of these factors were considered, a multivariate analysis using Cox's stepwise proportional hazards model was performed and revealed pancreatic invasion and perineural invasion to be the most significant prognostic factors. Tompkins Because we included only seven lower-third biliary tumors and four duodenal tumors in our series, we were unable to investigate potential prognostic factors in these two groups.
